SCHEMBL178425

SCHEMBL178425

Cc1ccc(C(=O)Nc2ccccc2)cc1

nearest known ligand 0.85

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 7/20 0.85
NPC1 O15118 6/20 0.85
MAPT P10636 2/20 0.85
SMN1; SMN2 Q16637 2/20 0.85
PTPN1 P18031 2/20 0.71
TDP1 Q9NUW8 1/20 0.70
HDAC2 Q92769 1/20 0.69
HDAC8 Q9BY41 1/20 0.69
HDAC6 Q9UBN7 1/20 0.69
NAMPT P43490 2/20 0.66
HTT P42858 2/20 0.65
ALDH1A1 P00352 1/20 0.65
HPGD P15428 1/20 0.65
CACNA1B Q00975 1/20 0.65
APBA1 Q02410 1/20 0.65
KMT2A Q03164 3/20 0.63
MEN1 O00255 2/20 0.63
POLB P06746 2/20 0.63
SIRT1 Q96EB6 1/20 0.63
KDM4E B2RXH2 1/20 0.63

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19500970 0.93 NPC1 (0.80) RAB9ANPC1MAPTSMN1; SMN2PTPN1
SCHEMBL16589432 0.93 PTPN1 (0.80) RAB9ANPC1MAPTSMN1; SMN2PTPN1
SCHEMBL13211986 0.93 NPC1 (0.80) RAB9ANPC1MAPTSMN1; SMN2PTPN1
SCHEMBL82305 0.92 RAB9A (1.00) RAB9ANPC1MAPTSMN1; SMN2PTPN1
Iodide SCHEMBL30758618 0.90 RAB9A (0.96) RAB9ANPC1MAPTSMN1; SMN2PTPN1
SCHEMBL12310125 0.90 RAB9A (1.00) RAB9ANPC1MAPTSMN1; SMN2TDP1
SCHEMBL14580374 0.90 RAB9A (1.00) RAB9ANPC1MAPTSMN1; SMN2TDP1
SCHEMBL822378 0.90 RAB9A (1.00) RAB9ANPC1MAPTSMN1; SMN2TDP1
SCHEMBL27181403 0.90 RAB9A (1.00) RAB9ANPC1MAPTSMN1; SMN2TDP1
SCHEMBL15214321 0.90 RAB9A (1.00) RAB9ANPC1MAPTSMN1; SMN2TDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 195 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240316015-A1 COMPOSITION AND METHOD FOR TREATING TUMORS NATURAL MEDICINE INSTITUTE OF ZHEJIANG YANGSHENGTANG CO., LTD. (CN) 2024-09-26 US claimed
EP-4282413-A1 COMPOSITION AND METHOD FOR TREATING TUMORS NATURAL MEDICINE INSTITUTE OF ZHEJIANG YANGSHENGTANG CO., LTD. (CN) 2023-11-29 EP claimed
CN-116462604-A Synthesis method of four quaternary ammonium salt derivatives and application of four quaternary ammonium salt derivatives as anti-staphylococcus aureus infection agents 西北工业大学宁波研究院 2023-07-21 CN claimed
EP-4140480-A1 DRUG COMBINATION AND USE THEREOF NATURAL MEDICINE INSTITUTE OF ZHEJIANG YANGSHENGTANG CO., LTD. (CN) 2023-03-01 EP claimed
WO-2022156727-A1 COMPOSITION AND METHOD FOR TREATING TUMORS 浙江养生堂天然药物研究所有限公司 2022-07-28 WO claimed
WO-2021213455-A1 DRUG COMBINATION AND USE THEREOF 浙江养生堂天然药物研究所有限公司 (CN) 2021-10-28 WO claimed
CN-111163761-A Targeted drugs related to trimethylamine and/or trimethylamine-N-oxide 普梭梅根公司 2020-05-15 CN claimed
US-6630512-B2 Antiinflammatory agents; autoimmune disease BIOGEN, INC. 2003-10-07 US claimed
US-20030018016-A1 Cell adhesion inhibitors BIOGEN IDEC MA, INC. 2003-01-23 US claimed
EP-0805796-B1 CELL ADHESION INHIBITORS BIOGEN INC (US) 2002-12-11 EP claimed
US-6376538-B1 ANTIINFLAMMATORY AGENTS; AUTOIMMUNE DISEASES BIOGEN, INC. 2002-04-23 US claimed
US-20250326709-A1 THE MICROWAVE-ASSISTED CATALYTIC AMIDATION OF ORGANIC AMINES WITH CARBOXYLIC ACIDS PURDUE RESEARCH FOUNDATION (US) 2025-10-23 US disclosed
CN-119264004-A Light-induced iridium metal catalytic synthesis method of N-aryl amide 平顶山学院 2025-01-07 CN disclosed
US-20240316015-A1 COMPOSITION AND METHOD FOR TREATING TUMORS NATURAL MEDICINE INSTITUTE OF ZHEJIANG YANGSHENGTANG CO., LTD. (CN) 2024-09-26 US disclosed
WO-2024151471-A1 HIGH-THROUGHPUT ASSAY BASED ON LIGAND-BIASED STRUCTURAL DYNAMICS RESPONSE THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) 2024-07-18 WO disclosed
US-5017686-A Production of aromatic polyamide using a fused ring stabilizer HUELS AKTIENGESELLSCHAFT (DE) 1991-05-21 US disclosed
US-5015680-A Production of a thermoplastically processable, aromatic polyamide using a 4-phenoxypyridine stabilizer HUELS AKTIENGESELLSCHAFT (DE) 1991-05-14 US disclosed
US-4952662-A Molding compounds comprising a thermoplastically processible, aromatic polyamide Huels Aktiengaellscaft (DE) 1990-08-28 US disclosed
US-4069340-A ARYLOXY DIMETHYL IMMONIUM CHLORIDES FROM DIMETHYL FORMAMIDE AND CORRESPONDING ARYL CHLOROFORMATES HOOKER CHEMICALS & PLASTICS CORPORATION (US) 1978-01-17 US disclosed
US-3983178-A Immonium salts and derivatives thereof HOOKER CHEMICALS & PLASTICS CORPORATION (US) 1976-09-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240316015-A1 COMPOSITION AND METHOD FOR TREATING TUMORS PDE4B, PDE4A, PDE4C RAB9A 2882/4885NPC1 4322/4885MAPT 2345/4885
US-20250326709-A1 THE MICROWAVE-ASSISTED CATALYTIC AMIDATION OF ORGANIC AMINES WITH CARBOXYLIC ACIDS NAAA, OAT, PAM RAB9A 2702/4885NPC1 4725/4885MAPT 470/4885
US-20030018016-A1 Cell adhesion inhibitors ICAM1, VCAM1, EPCAM RAB9A 1779/4885NPC1 2649/4885MAPT 2771/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.